From Yahoo Finance: 2025-05-25 18:02:00

Tandem Diabetes Care, Inc. (NASDAQ:TNDM) agrees to pay Roche $36 million to settle a patent infringement lawsuit over the t:slim X2 insulin pump. The deal resolves all pending and prospective litigation related to two European patents. Tandem will make an initial payment of $8 million and pay the remaining $28 million in four annual installments.

As part of the settlement, Tandem Diabetes and Roche have signed a cross-license agreement granting each other non-exclusive rights for patents of insulin delivery systems for the next ten years. This agreement ends all ongoing legal proceedings under the Unified Patent Court in France and Germany, reducing future legal risks for both companies.

The t:slim X2 pump will continue to be available commercially due to the settlement. The agreement lowers legal risks for both Tandem Diabetes Care, Inc. (NASDAQ:TNDM) and Roche moving forward. This development concludes all legal disputes related to the insulin delivery system patents, providing a more stable environment for both companies.



Read more at Yahoo Finance: Tandem Diabetes and Roche Reach a Patent Settlement